The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial
Year: 2011
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Abstract: In a phase-II multi-centre double-blinded trial, we evaluated haematological effects of oral hydroxycarbamide (HC) and magnesium (Mg) in patients with HbSC, aged 5-53 years old. Subjects were randomized to HC + placebo, Mg + placebo, HC + Mg, or placebo + placebo. The primary endpoint was the proportion of hyperdense red blood cells after 8 weeks. Thirty-six subjects were evaluable, but the study was terminated early because of slow enrollment. In the combined HC groups, mean cell volume and HbF were increased, but differences were not seen in hyperdense red cells or vaso-occlusive events. Mg had no effects. Further investigation of hydroxycarbamide as monotherapy in HbSC disease is warranted.
Source: British Journal of Haematology
Institutions: St. Jude Children's Research Hospital, Boston Children's Hospital, Harvard University, Rho (United States), The University of Texas Southwestern Medical Center, Cincinnati Children's Hospital Medical Center, Emory University, Boston University, University of Mississippi Medical Center, University of Mississippi, UCSF Benioff Children's Hospital, Children's Hospital of Philadelphia, University of Pennsylvania, Duke University, Duke Medical Center
Language: English
Subfield: Genetics (clinical)
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W1589993179
